Genetic aberrations in the CDK4 pathway and association with innate resistance to PD-1 blockade in acral melanoma

被引：0
|
作者：
Yu, Jiayi
Kong, Yan
Chi, Zhihong
Tang, Bixia
Sheng, Xinan
Si, Lu
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.9588
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9588
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PD-1 blockade and CDK4/6 inhibition augment nonoverlapping features of T cell activation in cancer (vol 220, e20220729, 2023)
    Ali, Lestat R.
    Garrido-Castro, Ana C.
    Lenehan, Patrick J.
    Bollenrucher, Naima
    Stump, Courtney T.
    Dougan, Michael
    Goel, Shom
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    Dougan, Stephanie K.
    JOURNAL OF EXPERIMENTAL MEDICINE, 2023, 220 (09):
  • [32] AUGMENTATION OF CD8 T CELL MEMORY VIA CDK4/6 INHIBITION CAN BE SEQUENTIALLY COMBINED WITH PD-1 BLOCKADE TO AVOID TOXICITIES
    Ali, Lestat
    Garrido-Castro, Ana
    Tolaney, Sara
    Dougan, Stephanie
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A981 - A981
  • [33] Genetic ablation of B2M leads to resistance to PD-1/PD-L1 blockade in vivo
    Zhang, Yanlei
    Ma, Hechun
    Han, Boang
    Li, Yi
    Yang, Ping
    Li, Zhen
    Feng, Dongxiao
    Ci, Lei
    Sun, Ruilin
    He, Daniel X.
    CANCER RESEARCH, 2024, 84 (06)
  • [34] Characterization of Immunosuppressive Myeloid Cells in Merkel Cell Carcinoma: Correlation with Resistance to PD-1 Pathway Blockade
    Tabachnick-Cherny, Shira
    Pulliam, Thomas
    Rodriguez, Haroldo J.
    Fan, Xinyi
    Hippe, Daniel S.
    Jones, Daniel C.
    Moshiri, Ata S.
    Smythe, Kimberly S.
    Kulikauskas, Rima M.
    Zaba, Lisa C.
    Paulson, Kelly G.
    Nghiem, Paul
    CLINICAL CANCER RESEARCH, 2024, 30 (06) : 1189 - 1199
  • [35] Differential Expression of Immune-Regulatory Genes Associated with PD-L1 Display in Melanoma: Implications for PD-1 Pathway Blockade
    Taube, Janis M.
    Young, Geoffrey D.
    McMiller, Tracee L.
    Chen, Shuming
    Salas, January T.
    Pritchard, Theresa S.
    Xu, Haiying
    Meeker, Alan K.
    Fan, Jinshui
    Cheadle, Chris
    Berger, Alan E.
    Pardoll, Drew M.
    Topalian, Suzanne L.
    CLINICAL CANCER RESEARCH, 2015, 21 (17) : 3969 - 3976
  • [36] Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce
    Kluger, Harriet M.
    Tawbi, Hussein A.
    Ascierto, Maria L.
    Bowden, Michaela
    Callahan, Margaret K.
    Cha, Edward
    Chen, Helen X.
    Drake, Charles G.
    Feltquate, David M.
    Ferris, Robert L.
    Gulley, James L.
    Gupta, Shilpa
    Humphrey, Rachel W.
    LaVallee, Theresa M.
    Le, Dung T.
    Hubbard-Lucey, Vanessa M.
    Papadimitrakopoulou, Vassiliki A.
    Postow, Michael A.
    Rubin, Eric H.
    Sharon, Elad
    Taube, Janis M.
    Topalian, Suzanne L.
    Zappasodi, Roberta
    Sznol, Mario
    Sullivan, Ryan J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (01)
  • [37] PD-1 blockade activates CD4 T cells and the innate immune response for glioblastoma eradication
    Klein, Sarah R.
    Speranza, Maria C.
    Gokhale, Prafulla C.
    Wilkens, Margaret K.
    Jones, Kristen L.
    Chaudhri, Apoorvi
    Kirschmeier, Paul T.
    Reardon, David A.
    Freeman, Gordon J.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [38] PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION
    Klein, Sarah R.
    Speranza, Maria Carmela
    Gokhale, Prafulla C.
    Wilkens, Margaret K.
    Jones, Kristen L.
    Kirschmeier, Paul T.
    Chaudhri, Apoorvi
    Reardon, David
    Freeman, Gordon J.
    NEURO-ONCOLOGY, 2017, 19 : 115 - 116
  • [39] PD-1 BLOCKADE ACTIVATES CD4 T CELLS AND THE INNATE IMMUNE RESPONSE FOR GLIOBLASTOMA ERADICATION
    Speranza, Maria Carmela
    Klein, Sarah R.
    Gokhale, Prafulla C.
    Wilkens, Margaret K.
    Jones, Kristen L.
    Chaudhri, Apoorvi
    Kirschmeier, Paul T.
    Reardon, David
    Freeman, Gordon
    NEURO-ONCOLOGY, 2018, 20 : 125 - 125
  • [40] Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world study
    Avital Klein-Brill
    Shlomit Amar-Farkash
    Keren Rosenberg-Katz
    Ronen Brenner
    Jürgen C. Becker
    Dvir Aran
    BJC Reports, 2 (1):
12345